JP2012525369A - 創傷および線維性障害の治療のためのホスホテトラヒドロピラン化合物 - Google Patents

創傷および線維性障害の治療のためのホスホテトラヒドロピラン化合物 Download PDF

Info

Publication number
JP2012525369A
JP2012525369A JP2012507839A JP2012507839A JP2012525369A JP 2012525369 A JP2012525369 A JP 2012525369A JP 2012507839 A JP2012507839 A JP 2012507839A JP 2012507839 A JP2012507839 A JP 2012507839A JP 2012525369 A JP2012525369 A JP 2012525369A
Authority
JP
Japan
Prior art keywords
compound
group
formula
aryl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012507839A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012525369A5 (enExample
Inventor
ディー．ロバートソン アラン
シルバ ディエゴ
アレクサンダー マクドナルド イアン
Original Assignee
ファーマキシス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファーマキシス リミテッド filed Critical ファーマキシス リミテッド
Publication of JP2012525369A publication Critical patent/JP2012525369A/ja
Publication of JP2012525369A5 publication Critical patent/JP2012525369A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2012507839A 2009-04-28 2010-04-28 創傷および線維性障害の治療のためのホスホテトラヒドロピラン化合物 Pending JP2012525369A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17341609P 2009-04-28 2009-04-28
US61/173,416 2009-04-28
PCT/IB2010/000960 WO2010125445A1 (en) 2009-04-28 2010-04-28 Phosphotetrahydropyran compounds for the treatment of wounds and fibrotic disorders

Publications (2)

Publication Number Publication Date
JP2012525369A true JP2012525369A (ja) 2012-10-22
JP2012525369A5 JP2012525369A5 (enExample) 2013-06-20

Family

ID=43031758

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012507839A Pending JP2012525369A (ja) 2009-04-28 2010-04-28 創傷および線維性障害の治療のためのホスホテトラヒドロピラン化合物

Country Status (10)

Country Link
US (1) US8557783B2 (enExample)
EP (1) EP2424542A4 (enExample)
JP (1) JP2012525369A (enExample)
KR (1) KR20120049183A (enExample)
AU (1) AU2010243314C1 (enExample)
CA (1) CA2760253A1 (enExample)
IL (1) IL215990A0 (enExample)
NZ (1) NZ596419A (enExample)
SG (1) SG175816A1 (enExample)
WO (1) WO2010125445A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6366598B2 (ja) * 2012-11-15 2018-08-01 タフツ ユニバーシティー ガレクチンタンパク質阻害剤を用いて被験体の眼の血管新生または繊維症を処置し、調節し、または、予防する方法、組成物、およびキット
CA3109137A1 (en) * 2018-08-10 2020-02-13 New York Univeristy Use of igf-2 receptor agonist ligands for treatment of angelman syndrome and autism
US12491203B2 (en) 2018-08-10 2025-12-09 New York University Use of mannose 6 phosphate and modifications thereof for memory enhancement and reducing memory impairment
MX2021007376A (es) 2018-12-19 2021-09-21 Univ Leland Stanford Junior Moléculas bifuncionales para el direccionamiento lisosómico y composiciones y métodos relacionados.
CN113368106B (zh) * 2020-02-25 2023-09-29 渐宽(苏州)生物科技有限公司 艾托莫德用于防治特发性肺纤维化的药物中的用途
CN113288890B (zh) * 2021-06-21 2022-02-22 南方医科大学南方医院 N-乙酰-l-半胱氨酸在制备预防和/或治疗运动损伤的药物中的应用
WO2023288033A1 (en) 2021-07-14 2023-01-19 Lycia Therapeutics, Inc. Asgpr cell surface receptor binding compounds and conjugates

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004501985A (ja) * 2000-07-11 2004-01-22 ファームアクシス・プロプライエタリー・リミテッド 新規化合物および方法
WO2004104015A2 (en) * 2003-05-20 2004-12-02 Pharmaxis Pty Ltd. Mannose-6-phosphonate compounds for the treatment of inflammatory diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2930943B1 (fr) 2008-05-07 2011-03-18 Centre Nat Rech Scient Nouvelles utilisations de derives de d-mannopyranose inhibiteurs de l'angiogenese
FR2930942B1 (fr) 2008-05-07 2011-03-04 Centre Nat Rech Scient Nouvelles utilisations de derives de d-mannopyranose activateurs de l'angiogenese

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004501985A (ja) * 2000-07-11 2004-01-22 ファームアクシス・プロプライエタリー・リミテッド 新規化合物および方法
WO2004104015A2 (en) * 2003-05-20 2004-12-02 Pharmaxis Pty Ltd. Mannose-6-phosphonate compounds for the treatment of inflammatory diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6014022046; ＩＬ　Ｆａｒｍａｃｏ ６０, 2005, ７２１-７２５ *

Also Published As

Publication number Publication date
AU2010243314C1 (en) 2015-11-12
IL215990A0 (en) 2012-01-31
EP2424542A1 (en) 2012-03-07
AU2010243314B2 (en) 2015-07-02
WO2010125445A1 (en) 2010-11-04
US8557783B2 (en) 2013-10-15
NZ596419A (en) 2014-01-31
SG175816A1 (en) 2011-12-29
KR20120049183A (ko) 2012-05-16
CA2760253A1 (en) 2010-11-04
AU2010243314A1 (en) 2011-12-01
US20120045455A1 (en) 2012-02-23
EP2424542A4 (en) 2012-12-19

Similar Documents

Publication Publication Date Title
US8557783B2 (en) Phosphotetrahydropyran compounds for the treatment of wounds and fibrotic disorders
US20240175022A1 (en) RUNX1 Inhibition for Treatment of Proliferative Vitreoretinopathy and Conditions Associated with Epithelial to Mesenchymal Transition
Pitha et al. Rho-kinase inhibition reduces myofibroblast differentiation and proliferation of scleral fibroblasts induced by transforming growth factor β and experimental glaucoma
KR20120046099A (ko) 섬유화를 억제하고 섬유화 질병을 치료하는 방법
KR20150115959A (ko) 안과 질환의 치료를 위한 옥실리핀 화합물
US20220226270A1 (en) Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use
Yu et al. Expression profiles of aquaporins in rat conjunctiva, cornea, lacrimal gland and Meibomian gland
US20120046333A1 (en) Methods and Compositions of PI-3 Kinase Inhibitors for Treating Fibrosis
Zhang et al. RO4929097, a selective γ-secretase inhibitor, inhibits subretinal fibrosis via suppressing Notch and ERK1/2 signaling in laser-induced mouse model
CA2896073C (en) Stimulation and enhancement of regeneration of tissues
JP2023518375A (ja) 治療方法
JP2001505219A (ja) 創傷の治癒および線維症の治療
Xu et al. The NLRP3 activation in infiltrating macrophages contributes to corneal fibrosis by inducing TGF-β1 expression in the corneal epithelium
CN102046165A (zh) 治疗纤维化紊乱的方法
CN114668849B (zh) Shh通路调控生物节律及其相关应用
US20240043396A1 (en) Methods of treating ocular fibrotic pathologies
US8283323B2 (en) Withanolide compounds as inhibitors of fibrosis and identification of molecular targets for anti-fibrotic drug development
WO2018115319A2 (en) Inhibitors of cytochrome p450 family 7 subfamily b member 1 (cyp7b1) for use in treating diseases
US20250170143A1 (en) Methods of treating ocular fibrotic pathologies
JP7429500B2 (ja) 角膜上皮障害治療剤
WO2013090991A1 (en) Tgf-beta therapy
US20250025438A1 (en) Derivative of aspartic acid and use thereof in treatment of metabolic diseases such as hepatic fibrosis and non-alcoholic hepatitis
Hou et al. Blockage of SUMO E1 enzyme inhibits ocular lens fibrosis by mediating SMAD4 SUMOylation
JP5685751B2 (ja) 結膜下線維芽細胞増殖抑制剤および結膜下線維芽細胞増殖抑制方法
CN117042774A (zh) 眼部病况的治疗

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20130426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140603

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140903

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140910

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20141003

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141010

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141104

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150512